trending Market Intelligence /marketintelligence/en/news-insights/trending/thM-9tjntseRkiMy1IkKIg2 content esgSubNav
In This List

UCB's psoriatic arthritis drug improved joint, skin symptoms in phase 2b trial

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


UCB's psoriatic arthritis drug improved joint, skin symptoms in phase 2b trial

UCB SA's psoriatic arthritis drug bimekizumab significantly improved joint and skin symptoms in a phase 2b trial.

Psoriatic arthritis is an inflammatory condition affecting the joints and skin.

The study met its primary goal with up to 46% of psoriatic arthritis patients who received the treatment seeing at least 50% improvement in joint symptoms after 12 weeks, compared with 7% of patients on placebo.

Among patients with skin lesions, 65% of those who received the drug experienced at least 90% skin clearance at week 12, compared with 7% who received placebo.

Bimekizumab has also demonstrated its efficacy in treating ankylosing spondylitis, a type of arthritis that mainly affects the spine. In a phase 2b study, 47% of patients receiving bimekizumab achieved at least 40% improvement in disease symptoms, compared to 13% receiving placebo after 12 weeks.